Voruciclib

Voruciclib (P1446A-05) is a novel multi-CDK inhibitor with IC50s of 90nM, 25nM, and 22nM for CDK4-CyclinD1, CDK1-Cyclin B, and CDK9-Cyclin T, respectively. Voruciclib specifically inhibits CDK4-mediated G1-S phase transition, arresting cell cycling and inhibiting cancer cell growth. The serine/threonine kinase CDK4 is found in a complex with D-type G1 cyclins and is the first kinase to become activated upon mitogenic stimulation, releasing cells from a quiescent stage into the G1/S growth cycling stage; CDK-cyclin complexes have been shown to phosphorylate the retinoblastoma (Rb) transcription factor in early G1, displacing histone deacetylase (HDAC) and blocking transcriptional repression.


Cat. No.: EX-A1056	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
25mg	715	Inquire
50mg	1100	Inquire
100mg	1695	Inquire

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	P1446A-05
CAS No.	1000023-04-0
Purity	>98%
Formula	C22H19ClF3NO5
Mol Weight	469.838
Appearance	Solid powder
Solubility	Soluble in DMSO, not in water
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Eliades P, et al. Cancer Biol Ther. 2016 Jul 2;17(7):778-84. PMID: 26810603. [2]. Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. Paiva C, et al. PLoS One. 2015 Nov 25;10(11):e0143685. PMID: 26606677.
CoA	CoA of Voruciclib

Smiles:	CN1CC[C@H]([C@@H]1CO)C1=C2OC(=CC(=O)C2=C(O)C=C1O)C1=CC=C(C=C1Cl)C(F)(F)F


		Search